The Dermatology Clinical Trials Unit is nationally recognized for developing and participating in clinical therapeutic trials. Clinical trials allow our patients to be exposed to experimental therapeutics. The trials unit is experienced in all areas of dermatologic clinical research from pre-Phase I to Phase IV. We are currently participating in a broad range of clinical trials of novel therapeutics for inflammatory and neoplastic skin disorders. The trials unit draws on the Division of Dermatology’s vast clinical experience.
Dermatology Clinical Trials Unit
Stephanie Farris, Clinical Research Coordinator, Main Campus
Phone: 314-747-8694 Fax: 314-362-6080
sefarris@wustl.edu
Justin Stout, Clinical Research Coordinator, Main Campus
Phone: 314-273-3737 Fax: 314-362-6080
justinjstout@wustl.edu
Mary Tabacchi, CRCC, Sr. Clinical Research Coordinator, All sites
Phone: 314-362-8171 Fax: 314-362-6080
mtabacchi@wustl.edu
Milan Anadkat, MD, Director, Clinical Trials Unit
manadkat@wustl.edu
Currently Enrolling Trials
Dr. Milan Anadkat- (COH)
A Phase II Study to Evaluate the Safety and Efficacy of OQL011 (topical nitroglycerin) on VEGFR Inhibitor-Associated Hand-foot Skin Reaction in Cancer Patients
A study to test whether BI 655130 (Spesolimab-IL-36) prevents flare-ups in patients with Generalized Pustular Psoriasis
A Phase 3, Randomized, Double-blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Bimekizumab (IL-1; SQ) in Subjects with Moderate to Severe Hidradenitis Suppurativa
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and
Safety of INCB054707 (Oral JAKi) in Participants with Hidradenitis Suppurativa
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of LY3041658 (CXCR1, 2) (Intravenous) in Adults with Moderate to Severe Hidradenitis Suppurativa
A pragmatic study of home versus office-based narrow band ultraviolet B phototherapy for the treatment of psoriasis (Short Title: Light Treatment Effectiveness (LITE) Study)
A Phase 2A, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ANB019 (SQ, IL-36 inh) in the Treatment of Acneiform Rash in Subjects with Cancer Receiving EGFRi or MEKi Therapy
An Open Label Exploratory Phase IIa Trial to Investigate the Safety and Efficacy of IFX-1 (C5a inhibitor; IV) in Treating Subjects with Pyoderma Gangrenosum
Dr. Heather Jones- (COH)
Clinical Study for Pediatric Patients (age 6-17) with Psoriasis to assess the efficacy, safety, and pharmacokinetics of Certolizumab Pegol (TNF antagonist)
Pivotal Phase III study: A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Subjects with Prurigo Nodularis
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel Group study to Evaluate the Efficacy and Safety of Dupilumab in Patients with Prurigo Nodularis who are Inadequately Controlled on Topical Prescription Therapies or when those Therapies are Not Advisable
Dr. Ann Martin- (West County)
Randomized, Double-Blind, Vehicle-Controlled, Multicenter Study to Assess the Efficacy and Safety of Methyl aminolevulinate hydrochloride (MAL) 16.8% cream (CD06809-41) versus vehicle cream in the treatment of thin and moderately thick, non-hyperkeratotic, non-pigmented actinic keratosis of the face and scalp when using daylight photodynamic therapy (DL-PDT)
A Phase 3, Double-Blind, Randomized, Vehicle Controlled, Efficacy and Safety Study of Ruxolitinib Cream followed by an Extension Period in Participants with Vitiligo
Dr. Amy Musiek- (COH)
Phase 2A, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of PF-06823859 (IFN antagonist) in Adult Subjects with Dermatomyositis
A Double Blind, Randomized, Vehicle Controlled, Crossover Study to Evaluate the Safety and Efficacy of Topical Naloxone Hydrochloride Lotion 0.5% for the Relief of Pruritus in Patients with the Mycosis Fungoides (MF) or Sézary Syndrome (SS) Forms Form of Cutaneous T-Cell Lymphoma (CTCL)
Evaluation of the Pharmacokinetics and Safety of Upadacitinib (JAK-inhibitor) in Pediatric Subjects (ages 2-11) with Severe Atopic Dermatitis
A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Repeated Dose Multi-Centered Study of the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of CBP-201 (IL-4 inhibitor) in Patients with Moderate to Severe Atopic Dermatitis
A Phase 2a, Randomized, Double-Blind, Placebo Controlled Study Investigating the Safety of Ritlecitinib (Oral JAKi) In Adult Participants with Alopecia Areata